Investors and Media

Investor Relations

Copyright Nasdaq. Minimum 15 minutes delayed.

Cancer is one of the most difficult diseases to treat. It is constantly changing, requiring new and more sophisticated therapies.

Replimune is pioneering a new generation of cancer treatments called oncolytic immunotherapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, generating a powerful patient-specific, systemic immune response.

Oncolytic immunotherapy enhances the effectiveness of immune checkpoint blockade and is expected to become the second cornerstone of immuno-oncology (IO) approaches, moving beyond incremental improvements in cancer treatment to help more patients overcome their disease.

Press Releases
Jul 19, 2018
WOBURN, Mass., July 19, 2018 (GLOBE NEWSWIRE) -- Replimune Group, Inc., a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform, today announced the pricing of its initial public offering of 6,700,000 shares of common stock at a public offering price of
Jun 22, 2018
Woburn, MA, June 22, 2018  – Replimune Group Inc., a biotechnology company developing next generation oncolytic immunotherapies, announced today it has appointed Dieter K. Weinand to its Board as an independent non-executive Director. “We are pleased to welcome Dieter to Replimune’s Board as we
Jun 11, 2018
Woburn, MA, June 11, 2018  – Replimune Group Inc., a biotechnology company developing next generation oncolytic immunotherapies, announced today it has appointed Hyam I. Levitsky, M.D. to the company’s Board as an independent non-executive Director. “Hy is a leading expert in immuno-oncology with
Events
More events are coming soon.
Presentations
More information is coming soon.